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Prostate cancer development and progression are as-
sociated with alterations in expression and function
of elements of cytokine networks, some of which can
activate multiple signaling pathways. Protein inhibi-
tor of activated signal transducers and activators of
transcription (PIAS)1, a regulator of cytokine signal-
ing, may be implicated in the modulation of cellular
events during carcinogenesis. This study was de-
signed to investigate the functional significance of
PIAS1 in models of human prostate cancer. We dem-
onstrate for the first time that PIAS1 protein expres-
sion is significantly higher in malignant areas of clin-
ical prostate cancer specimens than in normal
tissues, thus suggesting a growth-promoting role for
PIAS1. Expression of PIAS1 was observed in the ma-
jority of tested prostate cancer cell lines. In addition,
we investigated the mechanism by which PIAS1 might
promote prostate cancer and found that down-regu-
lation of PIAS1 leads to decreased proliferation and
colony formation ability of prostate cancer cell lines.
This decrease correlates with cell cycle arrest in the
G0/G1 phase, which is mediated by increased expres-
sion of p21CIP1/WAF1. Furthermore, PIAS1 overexpres-
sion positively influences cell cycle progression and
thereby stimulates proliferation, which can be mech-
anistically explained by a decrease in the levels of
cellular p21. Taken together, our data reveal an im-
portant new role for PIAS1 in the regulation of cell
proliferation in prostate cancer. (Am J Pathol 2012, 180:
2097–2107; DOI: 10.1016/j.ajpath.2012.01.026)
The development and progression of various human can-
cers are influenced by cytokines, some of which canactivate multiple signaling pathways. In human prostate,
cytokines regulate cellular events in chronic inflamma-
tion, premalignant lesions such as inflammatory atrophy
and high-grade intraepithelial neoplasia, and cancer.
Protein inhibitors of activated signal transducers and
activators of transcription (PIAS) are a group of multifunc-
tional proteins that play a role in the regulation of cyto-
kines and other cellular pathways. The family consists of
four members, PIAS1, PIASx (PIAS2), PIAS3, and PIASy
(PIAS4), that exist in two isoforms, with the exception of
PIAS1.1 Besides their DNA and protein binding ability,
which is mediated by the conserved SAP region, PIAS
proteins also contain a RING (really interesting new gene)
finger-like zinc-binding domain as well as a small ubiq-
uitin like modifier (SUMO) interaction motif, thus function-
ing as SUMO-E3 ligases.2 Therefore, PIAS can interact
with and modulate the activity of various proteins and
signaling cascades. PIAS1 and -3 were initially discov-
ered as inhibitors of signal transducers and activators of
transcription (STAT)1 and -3, respectively.3,4 STAT fac-
tors are a family of transcription factors which, on cyto-
kine [interferon (IFN), interleukin-6, and others] activa-
tion, become phosphorylated by Janus kinases (JAKs).
Phosphorylated STATs dimerize and translocate to the
nucleus, where they directly initiate gene activation.5
PIAS proteins can inhibit the DNA binding activity of
STATs.2 Furthermore, it has been shown that PIAS1
can SUMOylate STAT1 and thereby inhibits its IFN-
mediated transactivation.6 Besides JAK/STAT signal-
ing, PIAS proteins have also been implicated in the
regulation of the nuclear factor (NF) B pathway,
SMAD, and androgen receptor signaling.1 Cytokine-
induced responses are in addition controlled by sup-
pressors of cytokine signaling (SOCS). On the basis of
our previous findings demonstrating important roles of
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tate cancer, we initially hypothesized that selected
members of the PIAS family are implicated in control of
cell proliferation and apoptosis.7
Therefore, we investigated PIAS1 expression in human
prostate cancer cells and uncovered its functional signifi-
cance in this malignancy. In this study, we prove for the first
time that PIAS1 protein expression is significantly increased
in malignant tissues and demonstrate that down-regulation
of PIAS1 leads to reduced cell proliferation and colony
formation ability of prostate cancer cells. These growth-
inhibitory effects are due to elevated expression of the cell
cycle regulator protein p21CIP1/WAF1, which leads to a
G0/G1 arrest, whereas no significant effects on apoptosis
are observed. These findings were confirmed by PIAS1
overexpression experiments which resulted in an increase
in proliferation and reduced p21 expression.
Materials and Methods
Tissue Microarray and Immunohistochemistry
To evaluate differences in PIAS1 expression between ma-
lignant and benign prostate tissue, we constructed a tissue
microarray (TMA) of formalin-fixed, paraffin-embedded tis-
sue blocks from 90 previously untreated prostate cancer
patients who had undergone radical prostatectomy after
tumor diagnosis in a screening program performed in the
province of Tyrol by the Department of Urology, Innsbruck
Medical University.8 The use of the archive samples was
approved by the ethics committee of Innsbruck Medical
University. The TMA was assembled using a manual tissue
arrayer (Beecher Instruments, Sun Prairie, WI). Hematoxylin
eosin and p63/-methylacyl-CoA racemase (AMACR) im-
munohistochemistry double staining to control the histolog-
ical diagnosis, proliferating cell nuclear antigen (PCNA) and
Ki-67 staining for proliferation status, and PIAS1 immuno-
histochemistry were performed on a Discovery-XT staining
device (Ventana, Tucson, AZ). For PIAS1, Abcam (Cam-
bridge, UK) antibody clone EPR281Y was used (dilution
1:10). Immunohistochemical evaluation was done by a uro-
pathologist (G.S.) using the semiquantitative scoring sys-
tem “quickscore” combining the proportion of positive cells
and the average staining intensity.9
Cell Lines and Cell Culture
The human prostate cell lines LNCaP, PC3, DU-145, VCaP,
CWR22RV1, and BPH-1 were obtained from the American
Type Culture Collection (ATCC, Rockville, MD). The LNCaP
subline LNCaP-IL-6 was established in the presence of
IL-6 as described previously.10 Benign prostate epithelial
RWPE-1 cells were a gift fromDr. WilliamWatson (University
College Dublin, Ireland).11 The identity of the used cell lines
was confirmed by short tandem repeat analysis. PC3, DU-
145, and CWR22RV1 cells were cultured in RPMI 1640
supplemented with 10% fetal calf serum and 20 mmol/L
glutamine (both from PAA Laboratories, Pasching, Austria).
LNCaP cells were grown in RPMI 1640 containing 10% fetal
calf serum, 20mmol/L glutamine, 20mmol/L Hepes (Sigma,
Vienna, Austria), 4.5 g/L D-glucose (PAA Laboratories), and1% Na-Pyruvate (Lonza, Basel, Switzerland). VCaP cells
were grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal calf serum, 20 mmol/L glutamine,
and 4.5g/L D-glucose. RWPE-1 were cultured as previously
described.11
Short Interfering RNA Transfection
The following short interfering RNA (siRNA) sequences
were used for targeting human PIAS1: siPIAS1 A (sense:
5=-AAGGUCAUUCUAGAGCUUUAdTdT-3=; antisense 5=-UA-
AAGCUCUAGAAUGACCUUdTdT-3=), siPIAS1 B (sense:
5=-CGAAUGAACUUGGCAGAAAdTdT-3=; antisense: 5=-
UUUCUGCCCAAGUUCAUUCGdTdT-3=), sip21 (sense:
5=-CUUCGACUUUGUCACCGAGdTdt-3=; antisense: 5=-
CUCGGUGACAAAGUCGAAGdTdT-3=).12 A non-target-
ing siRNA pool (Dharmacon, Epsom, UK) was used as a
negative control. siRNA transfections were performed
with Lipofectamine 2000 reagent (Invitrogen, Lofer, Aus-
tria). All cell lines were transfected with either 25 nmol/L
siRNA against PIAS1 and/or p21 or control siRNA for 24
or 48 hours before mRNA and protein measurements,
respectively. Transfection was performed twice in studies
on proliferation and apoptosis.
PIAS1 Overexpression
Expression vector pEGFP-C1-PIAS1 and empty vector
pEGFP-C1 were generated by Dr. Yaron Galanty (Gur-
don Institute, Cambridge, UK) as described.13 Cells
were transfected with 3 g/mL of DNA using Fugene
HD transfection reagent (Roche, Basel, Switzerland)
for 48 or 72 hours following the manufacturer=s instruc-
tions.
Cytoplasmatic and Nuclear Fractionation
Fractions were obtained using NE-PER nuclear and cy-
toplasmic extraction kit (Pierce, Vienna, Austria) following
the manufacturer’s instructions.
Western Blot Analysis
Western blot analysis was performed as described
previously.14 The following antibodies were used: anti-
PIAS1 (dilution 1:750; Cell Signaling, Danvers, MA),
anti–cleaved poly(ADP-ribose) polymerase (cPARP;
dilution 1:1000; Promega, Madison, WI), anti-p21CIP1/
WAF1 (dilution 1:1000; Cell Signaling), anti-GAPDH (di-
lution 1:100,000; Chemicon, Vienna), and anti-lamin A
(1:5000; Abcam).
RNA Isolation and Quantitative Real-Time PCR
Quantitative real-time (qPCR) was performed as de-
scribed elsewhere.14 TaqMan gene expression assays
for PIAS1 and p21 were used (Applied Biosystems,
Brunn am Gebirge, Austria). HPRT1 was used as an
endogenous control: forward primer, 5=GCTTTCCTTG-
GTCAGGCAGTA3=; reverse primer; 5=GTCTGGCT-
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TATATCCAACACTTCGTTAMRA3=. Ct values of PIAS1 or
p21 and HPRT1, as assessed by ABI Sequence Detec-
tion Software, were used to calculate the Ct.
[3H]thymidine Incorporation Assay
Cells were seeded in triplicates onto 96-well plates. For
PIAS1 down-regulation, the cells were treated with 25
nmol/L of siRNA against PIAS1 or negative control
siRNA for 48 hours followed by a medium change and
second transfection for another 48 hours. For overex-
pression experiments, the cells were transfected with 3
g/mL of pEGFP-C1-PIAS1 or empty vector for 72
hours. Twenty-five microliters/well of [3H]thymidine (1
Ci/well) were added for the last 24 hours. DNA was
harvested on 96-well filter plates (Perkin-Elmer, Brunn
am Gebirge, Austria). Scintillation fluid (50 L) was
added, and radioactivity was quantified using Chame-
leon 5025 liquid scintillation counter (HVD Life Sci-
ences, Vienna, Austria).
Colony Formation Assay
Cells were transfected with siRNA against PIAS1 or con-
trol siRNA twice. The number of viable cells was deter-
mined using CASY cell counter system (Schärfe System,
Reutlingen, Germany). One thousand cells were seeded
into a 75-cm2 cell culture flask with 12 mL of medium
and incubated for 12 days. Subsequently, the cells were
fixed with 100% ice-cold methanol for 5 minutes and
stained with PBS containing 20% methanol and 0.5%
crystal violet (Sigma) for 2 minutes. Colony numbers were
determined and quantified with a CCD camera with green
electroluminescent transillumination.
Apoptosis Measurement
Cells were seeded onto six-well plates and transfected
twice with siRNA against PIAS1 or control siRNA. The
cells were trypsinized, and the pellets were resuspended
in propidium iodide (PI) buffer (0.2% Triton-X-100,
2 ng/mL Na-Citrate, and 0.05 mg/mL PI) and kept light-
protected at 4°C for 1 hour. To assess the percentage of
apoptotic cells, the sub-G1 peak was measured using
FACSCalibur (Becton Dickinson, Heidelberg, Germany).
Cell Cycle Distribution
PC3 and DU-145 cells were seeded onto six-well plates
and transfected with siRNA against PIAS1 or pEGFP-C1-
PIAS1 as well as respective controls for 48 hours. The
cells were trypsinized and centrifuged. Pellets were fixed
in 70% ice-cold ethanol for 30 minutes on ice. Afterward,
the cells were washed in PBS containing RNase A (100
g/mL) for 10 minutes, centrifuged, resuspended in PI
buffer, and kept light-protected at 4°C for 1 hour. Cell
cycle distribution was analyzed using FACSCalibur (Bec-
ton Dickinson). Cell cycle analysis was also performed
after thymidine block as described previously.12Immunofluorescence
Cells were seeded onto glass coverslips and allowed to
attach for 24 hours. Depending on the assay, they were
grown for 2 days without treatment (for localization stud-
ies) or transfected with siRNA against PIAS1 or control
siRNA (for siRNA efficiency studies and p21 expression
experiments). Subsequently, the cells were washed with
PBS and fixed with 4% paraformaldehyde for 10 minutes.
The cells were washed with PBS and permeabilized with
PBS/1% bovine serum albumin/0.2% Triton X100 for 5
minutes. After a 30-minute blocking step with PBS/1%
bovine serum albumin, coverslips were incubated for 1
hour with primary antibodies against PIAS1 (dilution 1:50;
Cell Signaling), p21 (WAF1/CIP1; dilution 1:50; Cell Sig-
naling), or cytokeratin 8/18 (dilution 1:500; Sigma) or
combinations of these. After washing, coverslips were
incubated with the following fluorescence-labeled sec-
ondary antibodies: goat anti-rabbit 555, donkey anti-
mouse 488, or goat anti-chicken 488 (all Invitrogen).
Figure 1. Increased expression of PIAS1 in human prostate cancer tissue. A:
Immunohistochemical staining of one representative core of a prostate can-
cer patient for PIAS1, p63/AMACR, PCNA, and Ki-67. Original magnification:
40 (left) or 400 (right). B: Quantification of the prostate cancer TMA
data.Coverslips were finally washed and mounted with
by cyto
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(Vector Laboratories, Burlingame, CA) on glass slides.
The cells were visualized using fluorescent microscopy
on a Zeiss Axio Imager M1 microscope.
Results
PIAS1 Expression Is Increased in Malignant
Human Prostate Tissue
To investigate PIAS1 expression patterns in benign
and malignant human prostate tissue, we performed a
TMA after immunohistochemical staining of 90 malig-
nant and 79 benign areas of prostate cancer speci-
mens. Immunohistochemistry of representative cores
revealed that PIAS1 staining is stronger in malignant
areas in comparison to benign tissue (Figure 1A).
Staining for p63 and AMACR determined benign and
malignant areas, respectively (Figure 1A). Stainings for
the commonly used markers PCNA and Ki-67 were
performed to determine the proliferative potential of the
cells (Figure 1A).15 Interestingly, the staining pattern of
PIAS1 correlated with that of PCNA and Ki-67, thus sug-
gesting a pro-proliferative role for PIAS1. Statistical analysis
of the TMA confirmed that the average staining intensity of
PIAS1 in tumors compared to benign tissue was signifi-
cantly increased (P 0.0003) (Figure 1B). The specificity of
the used PIAS1 antibody was proven by immunohistochem-
ical staining of siRNA-treated or PIAS-1 overexpressing
PC3 cells (see Supplemental Figure S1A at http://ajp.
Figure 2. PIAS1 is expressed in the nucleus of prostate cell lines. PIAS1 (A
Western blot analysis, respectively. Data represent mean value  SEM of thr
cells by immunofluorescence. Counterstainings of nuclei (blue) and cytoker
Original magnification, 400. D: Confirmation of PIAS1 nuclear localization
were used as cytoplasmic and nuclear markers, respectively.amjpathol.org).PIAS1 Is Expressed in Benign and Malignant
Prostate Cell Lines and Shows Nuclear
Localization
To determine PIAS1 expression in human prostate cell
lines, we measured mRNA levels by qPCR and protein
expression by Western blot. We detected PIAS1 mRNA
in all benign and malignant cell lines (Figure 2A). Nev-
ertheless, in comparison to mRNA expression, PIAS1
protein expression was more heterogenous. VCaP
cells showed the highest expression, whereas in
CWR22RV1 cells, expression of PIAS1 protein was al-
most below the detection limit (Figure 2B). Further-
more, immunofluorescence and cell fractionation meth-
ods were applied to determine the subcellular
localization of PIAS1. Both methods confirmed PIAS1
expression predominantly in the nuclei of PC3 cells
(Figure 2, C and D). The same results were obtained
with other prostate cell lines (data not shown). The
specificity of the PIAS1 antibody used for immunofluo-
rescence was controlled by PIAS1 down-regulation
and overexpression (see Supplemental Figure S1B at
http://ajp.amjpathol.org).
PIAS1 Down-Regulation Decreases Cell
Proliferation and Colony Formation Ability
PIAS1 is implicated in modulation of NFB, STAT1, and
androgen receptor signaling, which are known regula-
tors of cellular proliferation and apoptosis in prostate
cancer.2,16–19 Furthermore, the TMA results suggested
and (B) protein expression in prostate cell lines was assessed by qPCR and
pendent experiments. C: Localization of PIAS1 (red) was determined in PC3
8 (KRT 8/18; green) were performed to determine the localization of PIAS1.
plasmatic and nuclear fractionation of PC3 cell lysates. GAPDH and lamin A) mRNA
ee inde
atin 8/1an impact of PIAS1 on cellular proliferation. To address
firmed
, 630.
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specific siRNAs. Both siRNAs decreased PIAS1 mRNA
(see Supplemental Figure S2 at http://ajp.amjpathol.
org) and protein expression in PC3 cells by about 85%
(Figure 3A). The efficiency of the siRNA approach was
confirmed by immunofluorescence (Figure 3B).
To investigate effects of PIAS1 down-regulation on
cellular proliferation, we performed [3H]thymidine in-
corporation assays after down-regulation of PIAS1 in
PC3, DU-145, CWR22RV1, VCaP, and RWPE-1 cells.
Statistical analysis confirmed a significant decrease in
cell proliferation after PIAS1 knockdown. Thymidine
incorporation was reduced by approximately 50% to
75% in the investigated cell lines (Figure 4A).
CWR22RV1 cells, which express very low levels of
endogenous PIAS1 protein, showed no change in thy-
midine incorporation (Figure 4A). Similar results were
obtained when siRNA B was used in PC3 cells (see
Supplemental Figure S3A at http://ajp.amjpathol.org).
Down-regulation of PIAS1 in PC3 and DU-145 cells
also resulted in a significantly reduced number of col-
onies formed after 12 days in a colony-forming assay.
Furthermore, PIAS1 knockdown additionally reduced
colony size (Figure 4B). These findings support the
hypothesis that PIAS1 down-regulation negatively af-
fects cell proliferation. In addition, PIAS knock-down
with siRNA B also resulted in a reduced number of
colonies (see Supplemental Figure S3B at http://
ajp.amjpathol.org).
PIAS1 Overexpression Increases Cell
Proliferation
To confirm the findings obtained by PIAS1 knockdown,
we transfected PC3, DU-145, and CWR22RV1 cells with
the pEGFP-C1-PIAS1 expression vector for 72 hours and
subsequently measured proliferation by [3H]thymidine in-
corporation. Overexpression of PIAS1 significantly in-
creased proliferation (1.7- to 2.0-fold) in all cell lines
Figure 3. Inhibition of PIAS1 expression by siRNA. A:Western blot analysis a
for 48 hours. The percentage of cells treated with control siRNA was set as 10
t-test). B: PIAS1 (red) down-regulation after PIAS1 siRNA treatment was con
cytokeratin 8/18 (KRT 8/18; green) were performed. Original magnification(Figure 4C).PIAS1 Down-Regulation Has Minor Effects on
Apoptosis
To test the hypothesis that decreased proliferation
caused by PIAS1 down-regulation is a consequence of
an altered apoptosis rate, we transfected cells twice with
25 nmol/L of siRNA against PIAS1 and measured DNA
content after PI staining by flow cytometry. Analysis of the
sub-G1 peak revealed a slight change in apoptosis in
PC3 and RWPE-1 cells, which was not statistically signif-
icant (Figure 5A). To investigate a possible regulation of
apoptosis by an alternative method, we measured cleav-
age of PARP after treatment with either control or PIAS1
siRNA (Figure 5B). A slight increase in cPARP was ob-
served in PC3 and RWPE-1 cells, which confirmed the
findings obtained by flow cytometry.
PIAS1 Down-Regulation Increases the Number
of Cells in the G0/G1 Phase and Reduces the
Number of Cells in the S-Phase
Since previous results showed that PIAS1 down-regu-
lation leads to a reduction of proliferation, we com-
pared cell cycle distribution in PIAS1- and control
siRNA-treated PC3, DU-145, VCaP, RWPE-1, and
CWR22RV1 cells. Flow cytometric analysis proved that
PIAS1 down-regulation leads to a significant increase
in the percentage of cells in the G0/G1 phase as well
as a significant decrease of cells in the S-phase (Fig-
ure 6, A and B). This effect was confirmed when siRNA
B was used for PIAS1 silencing before the cell cycle
analysis (see Supplemental Figure S3C at http://ajp.
amjpathol.org). Furthermore, we observed a reduction
of the percentage of cells in the G2/M phase (Figure 6,
A and B). As expected, no alterations in cell cycle
distribution was observed in PIAS1-negative
CWR22RV1 cells. Our findings indicate that PIAS1 de-
sfection of PC3 cells with 25 nmol/L of siPIAS1 A, siPIAS1 B, or control siRNA
a represent mean  SEM from three independent experiments (***P  0.001,
by immunofluorescence in PC3 cells. Counterstainings of nuclei (blue) andfter tran
0%. Datpletion may prevent or delay the transition into the S
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AJP May 2012, Vol. 180, No. 5Figure 4. Expression of PIAS1 significantly influences proliferation and colony formation ability. A: Proliferation after PIAS1 down-regulation. Proliferation was
assessed by measurement of [3H]thymidine incorporation. Efficiency of the transfections was controlled by Western blot. The percentages of cells treated with
control siRNA were set as 100%. Data represent mean  SEM from three independent experiments (*P  0.05, **P  0.01, and ***P  0.001, t-test). B: Effect of
PIAS1 down-regulation on colony formation ability of PC3 and DU-145 cells was assessed by counting the number of colonies after 12 days. The percentage of
cells treated with control siRNA was set as 100%. Data represent mean SEM from three independent experiments (*P 0.05, ***P 0.001, t-Test). C: Proliferation
after PIAS1 overexpression, assessed as in A. The percentages of cells transfected with empty vector were set as 100%. Data represent mean  SEM from three
independent experiments (*P  0.05; **P  0.01; ***P  0.001, t-test).
Cells we
nt exper
ated with
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AJP May 2012, Vol. 180, No. 5phase of the cell cycle, thus being responsible for
decreased cell proliferation. To prove that PIAS1 sup-
ports cell cycle progression, cell cycle analysis was
also performed after overexpression of PIAS1. In con-
Figure 6. PIAS1 regulation influences cell cycle progression. Cells treated with s
Representative histograms of cell cycle distribution after PIAS1 down-regulation in P
in DU-145, VCaP, RWPE-1, and CWR22RV1 cells. The percentage of cells treated w
Figure 5. PIAS1 down-regulation does not significantly increase apoptosis. A:
content by flow cytometry. Data represent mean  SEM from three independe
Western blot from three independent experiments is shown. Ctrl represents cells treexperiments (**P 0.01, ***P 0.001, t-test).C:Representative histograms of cell cycle distribu
The percentage of cells transfected with empty vector (EV) was set as 100%. Data represent mcordance with the results obtained by PIAS1 down-regu-
lation, overexpression of PIAS1 resulted in a decrease of
cells in the G0/G1 and an increase of cells in the S phase as
well as the G2/M phase (Figure 6C).
r control siRNA were stained with PI buffer and analyzed by flow cytometry. A:
s well as statistical analysis of findings. B: Statistical analysis of cell cycle distribution
trol siRNA was set as 100%. Data represent mean  SEM from three independent
re transfected with PIAS1 siRNA or control siRNA twice and analyzed for DNA
iments. B: cPARP levels were assessed by Western blot analysis. A representative
200 g/mL cycloheximide to induce apoptosis. GAPDH served as loading control.iPIAS1 o
C3 cells a
ith contion after PIAS1 over-expression in PC3 cells aswell as statistical analysis of findings.
ean SEM from three independent experiments (**P 0.01, ***P 0.001, t-test).
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AJP May 2012, Vol. 180, No. 5Figure 7. PIAS1 expression influences p21 levels. A: p21 mRNA (upper panel) and protein (lower panel) expression after down-regulation of PIAS1 were
determined by qPCR and Western blot analysis, respectively. The percentages of cells treated with control siRNA were set as 100%. Data represent mean  SEM
from three independent experiments (**P  0.01, ***P  0.001, t-test). B: Increased p21 (green) expression after down-regulation of PIAS1 (red) was confirmed
by immunofluorescence. Original magnification, 630. C: Western blot analysis of p21 protein expression after overexpression of PIAS1. The percentage of cells
transfected with empty vector was set as 100%. Data represent mean  SEM from three independent experiments (**P  0.01, ***P  0.001, t-test).
midine
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Regulator p21
To further analyze themechanismbywhich PIAS1 regulates
cell cycle progression, we determined p21 expression after
down-regulation or overexpression of PIAS1. p21 is a mem-
ber of the CIP/KIP family of cyclin-dependent kinase G1/S
phase transition inhibitors.20–22 Furthermore, it was shown
that p21 induction reduces prostate cancer cell growth.23
We transfected PC3, DU-145, and CWR22RV1 cell lines
with PIAS1 siRNA and measured p21 expression by qPCR
and Western blot (Figure 7A). Both analyses confirmed a
significantly increased p21 expression after PIAS1 silencing
in PC3 (5.5-fold) and DU-145 cells (approximately three-
fold). Taken together, our data reveal that the increase in
p21 expression is a result of transcriptional regulation. The
results were confirmed with siRNA B (see Supplemental
Figure S3D at http://ajp.amjpathol.org). As a control, p21
expression was not affected in CWR22RV1 cells which ex-
press very low levels of PIAS1 protein (Figure 7A). In addi-
tion, these cells did not show any change in proliferation
after siRNA treatment (Figure 4A). We confirmed those find-
ings by immunofluorescence in PC3 and DU-145 cell lines.
p21 staining highly increased in siRNA-treated cells (Figure
7B). Immunofluorescence also revealed that p21, following
PIAS1 siRNA treatment, predominantly shows nuclear local-
ization, which is known to be associated with its cell cycle
inhibitory activity.24,25 To provide further support for the
hypothesis that PIAS1 regulates p21 expression in prostate
Figure 8. p21 accumulation is involved in mediating the cell cycle arrest a
combination of both. Cell cycle analysis was performed by flow cytometry (
GAPDH was used as an internal control. PC3 cells were growth arrested by thy
expression levels (D). Three independent experiments were performed.cancer, we also measured p21 levels after overexpressionof PIAS1. Therefore, we transfected PC3, DU-145, and
CWR22RV1 cells with pEGFP-C1-PIAS1 or empty vector.
Western blot analysis revealed that PIAS1 overexpression
leads to a significant decrease in p21 levels in PC3 and
DU-145 cells and to a slight decrease in its expression in
the CWR22RV1 cell line (Figure 7C). Taken together, these
findings clearly demonstrate that PIAS1 significantly influ-
ences expression levels of the cell cycle inhibitor p21.
Cell Cycle Arrest Following PIAS1 Silencing Is
Mediated by p21
To address the question whether the observed cell cycle
arrest after PIAS1 down-regulation is enforced by p21, we
treated the cells with siRNAs against PIAS1 or p21 or the
combination of both and measured cell cycle distribution
under those conditions. As demonstrated before, down-
regulation of PIAS1 leads to an increase in p21 levels and,
subsequently, to an enrichment of cells in the G1 phase as
well as a decrease of cells in the S phase. These effects
could be reversed after a combined down-regulation of
PIAS1 and p21 (Figure 8, A and B). To exclude the possi-
bility that p21 accumulation is mediated by the G1 arrest,
wemeasured p21 levels in S phase-arrested cells (Figure 8,
C and D). Western blot results confirmed that treatment with
PIAS1 siRNA leads to p21 accumulation independently of
cell cycle position, thus indicating that cell cycle arrest is a
S1 knockdown. PC3 cells were treated with siRNA against p21, PIAS1, or a
expression of PIAS1 and p21 were determined by Western blot analysis (B).
block followed by cell cycle analysis (C) and determination of p21 and PIAS1fter PIA
A), andconsequence of p21 increase.
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The functional role of PIAS proteins in human malignancies
has not been clarified yet. Brantley and colleagues26 dem-
onstrated that loss of PIAS3 in glioblastoma multiforme
leads to enhanced cellular proliferation through increased
STAT3phosphorylation, whileCoppola et al27 showa reduced
expression of PIAS1 associated with colon cancer develop-
ment. Studies that systematically address PIAS1 protein ex-
pression patterns and its role in regulation of proliferation and
cell death in cancer have not been performed yet.
In this work, we prove for the first time that PIAS1 protein
expression is significantly increased in tumor tissue in com-
parison to benign areas of specimens obtained from pa-
tients with prostate cancer. These results are in line with the
observations from Li and colleagues28 who reported on an
increase in PIAS1 mRNA in prostate tumor cases.
It was shown that androgenic hormones up-regulate
PIAS1 expression.29 Other steroids or peptide growth
factors, whose expression is dysregulated at diverse
stages of prostate carcinogenesis, may also influence
PIAS1 levels, and regulation of PIAS1 by these molecules
may be a subject of future investigations. In view of our
results, previous findings by Gross and colleagues16 who
described the role of PIAS1 as a co-activator of androgen
receptor may be particularly relevant in prostate cancer.
Thus, PIAS1 may in addition contribute to enhanced pro-
liferation or decreased apoptosis of prostate cancer cells
through stimulation of androgen receptor activity.
In our study, the staining pattern of PIAS1 protein in
prostate tissues correlated with that of the proliferation
markers PCNA and Ki-67, thus suggesting a growth-pro-
moting role for PIAS1 in prostate cancer.15 This assumption
was supported by our in vitro results. We show that PIAS1
down-regulation decreases proliferation and colony forma-
tion ability of prostate cancer cell lines. This decrease can
be explained by a p21-induced cell cycle arrest. Further-
more, PIAS1 over-expression leads to an increase in prolif-
eration and reduced p21 levels. Our results also indicate
that the presence of p21 in cancer cells plays an important
role in the inhibitory effect of PIAS1 on cell growth.
In prostate cancer, induction of p21 after inositol
hexaphosphate or silibinin treatment was reported.30,31
Those results are consistent with our data, that p21 in-
duction leads to a G1 arrest and growth inhibition of
prostate cancer cells. Furthermore, Chen32 et al showed
in a model of acute pancreatitis that PIAS1 down-regula-
tion leads to an increase in p21 levels which induces cell
cycle arrest and subsequent apoptosis thus supporting
our results. Interestingly, a tumor suppressive effect of
p21 was not observed in many cellular systems.25,33 It
was reported that p21 has multiple functions depending
on binding partners and its subcellular localization.34 It
was proposed that nuclear retention of p21 is associated
with enhanced G1 arrest and cell death in cells in which
heat-shock protein 27 or Akt were silenced, whereas
cytoplasmic sequestration of p21 delays apoptosis.35,36
The subcellular localization of p21 may be a determinant
for the regulatory functions of p21. In the present study,
p21 was expressed in the nucleus following PIAS1 down-
regulation. This indicates a tumor-suppressive effect ofp21 thus explaining the observed cell cycle arrest and
inhibition of proliferation after siRNA treatment.
The regulation of p21 by PIAS1 in prostate cancer has
not been completely clarified but several mechanisms
could be considered. For example, SUMOylation of p53 or
p73 by PIAS1 could account for the observed effects. Both
tumor suppressors can directly influence p21 expres-
sion.37,38 Since p53 is absent in PC3 and mutated in DU-
145 cells, a p73-dependent mechanism being responsible
for the effects of PIAS1 is more probable.39 This hypothesis
is supported by Munarriz and colleagues,38 who showed
that PIAS1, which is expressed predominantly during the S
phase of the cell cycle, can bind to and SUMOylate p73,
thereby inhibiting the transcriptional activity of p73, which
leads to a decrease in p21 in lung cancer and osteosar-
coma cells. Furthermore, it has been shown that also PIASy
can interact with p73 in HEK293 cells.40 However, on the
basis of our results, we cannot exclude p73-independent
regulation of p21 by PIAS1.
The present results indicate that themolecules that inhibit
cytokine signaling are involved in prostate cancer regula-
tory processes by multiple mechanisms. In this context,
PIAS1 and SOCS-3 promote tumorigenesis in prostate can-
cer cell lines through different mechanisms. We demon-
strated that SOCS-3 prevents apoptosis through inhibition
of extrinsic and intrinsic apoptotic pathways and regulation
of Bcl-2 expression in androgen-insensitive cell lines.13 In
androgen-sensitive prostate cancer cells, androgenic up-
regulation of SOCS-3 resulted in inhibition of proliferation
and secretion of prostate-specific antigen induced by male
sexual hormones.41 Tumor-promoting effects of PIAS1 in
prostate cancer were observed in this study in cell lines
irrespective of their androgen sensitivity. In contrast to
PIAS1, SOCS-1 retards cell cycle progression. It inhibits
expression of cyclin-dependent kinases 2 and 4 and cyclins
D1 and E.42 The interest for the role of endogenous inhibi-
tors of cytokine signaling could be explained by the fact that
chronic inflammation is associated with prostate cancer
development, at least in a subgroup of patients.43 A better
understanding of action of cytokines and their endogenous
inhibitors in pre-malignant prostate lesions and cancer is
therefore necessary to improve therapy and prevention of
prostate carcinogenesis. For this reason, all elements of cyto-
kine signaling pathways are a subject of intensive investiga-
tions. As stated above, suppressors of cytokine signaling are
likely to regulate tumorigenesis also by inflammation-indepen-
dent mechanisms, in particular in advanced cancer.
In summary, we show for the first time that PIAS1 protein
expression is increased in human prostate cancer and
identify a new functional role for PIAS1 in the regulation of
proliferation and cell cycle in prostate cancer cell lines. On
the basis of these results, we suggest that PIAS1 may be
considered a potential target for the development of im-
proved therapies in prostate cancer.
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